|
|
|
HOME
| PRODUCTS |
OSTEOPOROSIS
|
Otosclerosis|
BIOTINIDASE
DEFICIENCY |
RESEARCH |
CONTACT US |
PRIVACY
POLICY
J. D. Ringe, C. Kipshoven, A. Coster and R. Umbach Department of Internal Medicine 4, Klinikuni Leverkusen, Leverkusen, Germany
Are Antiresorptive Agents the Ultimate Therapy for Osteoporosis? P.D. Delmas INSERM Research Unit 403 and Claude Bernard University of Lyon, France New Evidence For the Fracture–Reducing Effectiveness of Monofluorophosphate: Practical Implications Bone and Cartilage Metabolism Unit University of Liege Belgium-Department of Epidemiology & public health, Liege Belgium-Georgetown University Medical Center, Washington, D.C
Intermittent or Continuous Treatment with Monofluorophosphate alone in the combination with Antiresorptive: Current data and perspectives. J.D. Ringe Dept. Of Internal Medicine 4, Klinikum Leverkusen, University of Cologne, Germany
McGuirt Wt and others. Linkage of a gene for otosclerosis to chromosome 15q25-q26 and identification of a candidate gene: Aggrecan. ARO abstracts, #428, 1998. Nadol JB. Otosclerosis: clinical aspects and management. Audio-Digest Otolaryngology 31,#2, Jan 15, 1998 Shambaugh GE Jr. Fluoride therapy for otosclerosis.Arch Otolaryngol Head Neck Surg 1990 Oct;116(10):1217 Comparison of two topical preparations for the treatment of onychomycosis: Melaleuca alternifolia (tea tree) oil and clotrimazole.Buck DS, Nidorf DM, Addino, JG, Comparion Of Two Topical Preparations or the Treatment of Onychomycosis: Melaleuca alternifolia (tea tree oil) and Clotrimazole. JfamPract 38: 601-605, 1994
Treatment of toenail onychomycosis with 2% butenafine and 5% Melaleuca alternifolia (tea tree) oil in creamT. A. Syed, Z. A. Qureshi, S. M. Ali, S Ahmad, S. A. Ahmad (1999)
|
|
These statement on mericon-industries.com have not been evaluated by the Food and Drug Administration. The products and research on this website are not intended to diagnose, treat or cure or prevent disease.
All Rights Reserved 1998-2010 |